Athira (ATHA) Q2 Loss Narrows 74%

Athira Pharma (NASDAQ:ATHA), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105. Revenue was again zero, as expected for a clinical-stage company. The quarter showcased significant reductions in research and development expenses following the pipeline restructuring, but also highlighted an urgent need for future partnership or funding as the company advances ATH-1105 for amyotrophic lateral sclerosis (ALS) trials. Source: Analyst estimates for the quarter provided by FactSet. Athira Pharma develops therapeutics for neurodegenerative conditions, including ALS and Alzheimer’s disease. Its central strategy is to harness the hepatocyte growth factor (HGF) pathway with small molecule drugs, aiming to slow or reverse neurodegeneration by promoting nerve cell function and survival.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool